99th Dahlem Conference on Infection, Inflammation and Chronic Inflammatory Disorders: The normal gut microbiota in health and disease

Clinical and Experimental Immunology

Volumn 160, Issue 1, 2010, Pages 80-84

  Backhed F ^a,b  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Atherosclerosis; Diabetes; Normal gut microbiota; Obesity

Indexed keywords

ANTIBIOTIC AGENT; CD14 ANTIGEN; CHOLINE; DNA 16S; FATTY ACID; GLUCAGON; MYELOID DIFFERENTIATION FACTOR 88; POLYSACCHARIDE; SOMATOSTATIN; TOLL LIKE RECEPTOR 4; TRIMETHYLAMINE;

ATHEROSCLEROSIS; BACTEROIDES THETAIOTAOMICRON; BIOINFORMATICS; CARDIOVASCULAR DISEASE; CHLAMYDOPHILA PNEUMONIAE; CONFERENCE PAPER; DIET; DISEASE PREDISPOSITION; ENDOTOXEMIA; ENERGY ABSORPTION; ENTERITIS; ENVIRONMENTAL EXPOSURE; FATTY ACID BLOOD LEVEL; GENOME; GENOTYPE; GLUCAGON BLOOD LEVEL; GLUCOSE TOLERANCE; HUMAN; INFLAMMATORY DISEASE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTESTINE FLORA; METABOLIC DISORDER; METABOLIC SYNDROME X; METAGENOMICS; MICROBIAL DIVERSITY; MICROBIOME; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SOMATOSTATIN BLOOD LEVEL; STEATOSIS; TWINS;

ANIMALS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HUMANS; INFLAMMATION; INTESTINES; METAGENOME; MICE; OBESITY; POLYSACCHARIDES;

EID: 77949344367     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2010.04123.x     Document Type: Conference Paper

References (47)

1. Xu J, Gordon JI. Inaugural article: honor thy symbionts. Proc Natl Acad Sci USA 2003; 100:10452-9.
2. Bäckhed F, Ley RE, Sonnenburg JL, Peterson DA, Gordon JI.Host-bacterial mutualism in the human intestine. Science 2005; 307:1915-20.
3. Eckburg PB, Bik EM, Bernstein CN et al. Diversity of the human intestinal microbial flora. Science 2005; 308:1635-8.
4. Gill SR, Pop M, Deboy RT et al. Metagenomic analysis of the human distal gut microbiome. Science 2006; 312:1355-9.
5. Ley RE, Bäckhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JI. Obesity alters gut microbial ecology. Proc Natl Acad Sci USA 2005; 102:11070-5.
6. Turnbaugh PJ, Hamady M, Yatsunenko T et al. A core gut microbiome in obese and lean twins. Nature 2009; 457:480-4.
7. Nadal I, Santacruz A, Marcos A et al. Shifts in clostridia, bacteroides and immunoglobulin-coating fecal bacteria associated with weight loss in obese adolescents. Int J Obes (Lond) 2009; 33:758-67.
8. Kalliomaki M, Collado MC, Salminen S, Isolauri E. Early differences in fecal microbiota composition in children may predict overweight. Am J Clin Nutr 2008; 87:534-8.
9. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. Nature 2006; 444:1022-3.
10. Turnbaugh PJ, Bäckhed F, Fulton L, Gordon JI. Diet-induced obesity is linked to marked but reversible alterations in the mouse distal gut microbiome. Cell Host Microbe 2008; 3:213-23.
11. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006; 444:1027-31.
12. Xu J, Bjursell MK, Himrod J et al. A genomic view of the human-Bacteroides thetaiotaomicron symbiosis. Science 2003; 299:2074-6.
13. Juhr NC, Franke J. A method for estimating the available energy of incompletely digested carbohydrates in rats. J Nutr 1992; 122:1425-33.
14. McNeil NI. The contribution of the large intestine to energy supplies in man. Am J Clin Nutr 1984; 39:338-42.
15. Drucker DJ. The role of gut hormones in glucose homeostasis. J Clin Invest 2007; 117:24-32.
16. Uribe A, Alam M, Johansson O, Midtvedt T, Theodorsson E. Microflora modulates endocrine cells in the gastrointestinal mucosa of the rat. Gastroenterology 1994; 107:1259-69.
17. Bäckhed F, Crawford PA. Coordinated regulation of the metabolome and lipidome at the host-microbial interface. Biochim Biophys Acta 2009; in press.
18. Reinhardt C, Reigstad CS, Backhed F. Intestinal microbiota during infancy and its implications for obesity. J Pediatr Gastroenterol Nutr 2009; 48:249-56.
19. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006; 444:860-7.
20. ShiH,Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS. TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest 2006; 116:3015-25.
21. Solinas G, Vilcu C, Neels JG et al. JNK1 in hematopoietically derived cells contributes to diet-induced inflammation and insulin resistance without affecting obesity. Cell Metab 2007; 6:386-97.
22. Brun P, Castagliuolo I, Di Leo V et al. Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis. Am J Physiol Gastrointest Liver Physiol 2007; 292:G518-25.
23. Creely SJ, McTernan PG, Kusminski CM. Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. Am J Physiol Endocrinol Metab 2007; 292:E740-7.
24. Cani PD,Amar J, IglesiasMAet al.Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007; 56:1761-72.
25. Mydel P, Takahashi Y, Yumoto H et al. Roles of the host oxidative immune response and bacterial antioxidant rubrerythrin during Porphyromonas gingivalis infection. PLoS Pathog 2006; 2:e76.
26. Johnson GB, Riggs BL, Platt JL. A genetic basis for the 'Adonis' phenotype of low adiposity and strong bones. FASEB J 2004; 18:1282-4.
27. Tsukumo DML, Carvalho-Filho MA, Carvalheira JBC et al. Loss-of-function mutation in toll-like receptor 4 prevents diet-induced obesity and insulin resistance. Diabetes 2007; 56:1986-98.
28. Cani PD, Neyrinck AM, Fava F et al. Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia 2007; 50:2374-83.
29. Cani PD, Bibiloni R, Knauf C et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice.Diabetes 2008; 57:1470-81.
30. Cani PD, Possemiers S, Van deWiele T et al. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 2009; 58:1091-103.
31. Ghoshal S, Witta J, Zhong J, de Villiers W, Eckhardt E. Chylomicrons promote intestinal absorption of lipopolysaccharides. J Lipid Res 2009; 50:90-7.
32. Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 2001; 414:799-806.
33. Bäckhed F, Ding H, Wang T et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci USA 2004; 101:15718-23.
34. Bäckhed F, Manchester JK, Semenkovich CF, Gordon JI. Mechanisms underlying the resistance to diet-induced obesity in germfree mice. Proc Natl Acad Sci USA 2007; 104:979-84.
35. Dumas ME, Barton RH, Toye A et al. Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice. Proc Natl Acad Sci USA 2006; 103:12511-6.
36. Jiang X-C, Li Z, Liu R. Phospholipid transfer protein deficiency impairs apolipoprotein-B secretion from hepatocytes by stimulating a proteolytic pathway through a relative deficiency of vitamin E and an increase in intracellular oxidants. J Biol Chem 2005; 280:18336-40.
37. Saikku P, Leinonen M, Tenkanen L et al. Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study. Ann Intern Med 1992; 116:273-8.
38. DeStefano F, Anda RF, Kahn HS, Williamson DF, Russell CM. Dental disease and risk of coronary heart disease and mortality. BMJ 1993; 306:688-91.
39. Erridge C. The roles of pathogen-associated molecular patterns in atherosclerosis. Trends Cardiovasc Med 2008; 18:52-6.
40. Ott SJ, El Mokhtari NE, Musfeldt M et al. Detection of diverse bacterial signatures in atherosclerotic lesions of patients with coronary heart disease. Circulation 2006; 113:929-37.
41. Holmes E, Loo RL, Stamler J et al. Human metabolic phenotype diversity and its association with diet and blood pressure. Nature 2008; 453:396-400.
42. Kiechl S, Lorenz E, Reindl M et al. Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med 2002; 347:185-92.
43. Bjorkbacka H,Kunjathoor VV,Moore KJ et al. Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways. Nat Med 2004; 10:416-21.
44. Michelsen KS,Wong MH, Shah PK et al. Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc Natl Acad Sci USA 2004; 101:10679-84.
45. Wright SD, Burton C, Hernandez M et al. Infectious agents are not necessary for murine atherogenesis. J Exp Med 2000; 191:1437-42.
46. Brugman S, Klatter FA, Visser JT et al. Antibiotic treatment partially protects against type 1 diabetes in the Bio-Breeding diabetesprone rat. Is the gut flora involved in the development of type 1 diabetes? Diabetologia 2006; 49:2105-8.
47. Wen L, Ley RE, Volchkov PY et al. Innate immunity and intestinal microbiota in the development of Type 1 diabetes. Nature 2008; 455:1109-13.